Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
$48.4 million in cash at the end of Q2 2023 expected to provide operating runway into 2025Fully prepaid and retired debt facilityAuthorized $7.5 million stock repurchase programLA JOLLA, Calif. (BUSINESS WIRE) $EQ Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding.
$71.0 million cash balance at the end of 2022 expected to provide cash runway into 2025
Acquired Bioniz Therapeutics, including two first-in-class clinical-stage assets, EQ101 and EQ102, and. | March 23, 2023
$71.0 million cash balance at the end of 2022 expected to provide cash runway into 2025 Acquired Bioniz Therapeutics, including two first-in-class clinical-stage. | March 23, 2023
Equillium grants Ono an option to purchase rights to itolizumabEquillium to receive an upfront payment of approximately $26.0M (¥3.5B); eligible to receive up to approximately $138.5M (¥18.7B) in option exercise and milestone paymentsOno to fund Equillium’s continued research and development of itolizumab during the.